Staff in clinical research jobs at GlaxoSmithKline (GSK) are to work alongside a number of independent scientists as part of the company's new open laboratory project in Spain.
Eight scientists based at six organisations from four countries have taken up open lab placements at the company's research campus in Tres Cantos, as part of a trial programme aimed at stimulating collaborative research.
Hailing from the US, UK, Spain and South Africa, the researchers will work in conjunction with GSK staff to study new methods of treating diseases affecting developing nations, benefiting from the company's expertise and facilities.
Projects include research into treatments for drug-resistant tuberculosis, several malaria studies and analysis of a new approach to combating the parasites that cause leishmaniasis.
Nick Cammack, GSK senior vice-president and head of the Tres Cantos Medicines Development Campus, said: "The initiation of these research projects at Tres Cantos represents an exciting step forward in a new, more open approach to stimulate research into new medicines."
In May 2011, GSK allied with the PATH Malaria Vaccine Initiative and the University College of Medicine, Malawi to conduct a new usage study of an innovative developmental malaria vaccine.